Insmed (INSM) Stock Undervalued by 54.3% Based on DCF Analysis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2d ago
0mins
Source: Yahoo Finance
- Stock Performance: Insmed's recent closing price of $175.97 reflects a remarkable 169.7% return over the past year, despite a 9.9% decline in the last month, highlighting the tension between short-term volatility and long-term growth potential.
- Cash Flow Forecast: The Discounted Cash Flow (DCF) model projects Insmed's free cash flow to reach $2.855 billion by 2030, while the current free cash flow stands at a loss of $906.7 million, indicating a significant improvement in future profitability.
- Intrinsic Value Assessment: The DCF analysis estimates Insmed's intrinsic value at approximately $385.32 per share, suggesting a 54.3% undervaluation compared to the current market price, presenting a potential buying opportunity for investors.
- Price-to-Book Analysis: Insmed's price-to-book ratio is 39.69x, significantly higher than the biotech industry average of 2.70x; however, the absence of a clear “fair ratio” model complicates the assessment of its current valuation.
Analyst Views on INSM
Wall Street analysts forecast INSM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INSM is 200.31 USD with a low forecast of 145.00 USD and a high forecast of 240.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Analyst Rating
17 Buy
1 Hold
0 Sell
Strong Buy
Current: 175.970
Low
145.00
Averages
200.31
High
240.00
Current: 175.970
Low
145.00
Averages
200.31
High
240.00
About INSM
Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
